Experimental Hematology and Oncology 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.TRIB3 silencing promotes the downregulation of Akt pathway and PAX3-FOXO1 in high-risk rhabdomyosarcoma
In this study, the main aim was to address this challenge by investigating regulators of FOXO1. Specifically, we focused on TRIB3, a potential regulator of the fusion protein in RMS. Our findings revealed a prominent TRIB3 expression in RMS tumors, highlighting its correlation with the presence of fusion protein. By conducting TRIB3 genetic inhibition experiments, we observed an impairment on cell proliferation. Notably, the knockdown of TRIB3 led to a decrease in PAX3-FOXO1 and its target genes at protein level, accompanied by a reduction in the activity of the Akt signaling pathway. Additionally, inducible silencing of T...
Source: Experimental Hematology and Oncology - April 5, 2024 Category: Cancer & Oncology Source Type: research
Novel insights into TCR-T cell therapy in solid neoplasms: optimizing adoptive immunotherapy
In conclusion, this review depicts our current understanding of TCR-T cell therapy in solid neoplasms, and provides new perspectives for expanding its clinical applications and improving therapeutic efficacy. (Source: Experimental Hematology and Oncology)
Source: Experimental Hematology and Oncology - April 3, 2024 Category: Cancer & Oncology Source Type: research
Vaccination with a combination of STING agonist-loaded lipid nanoparticles and CpG-ODNs protects against lung metastasis via the induction of CD11bhighCD27low memory-like NK cells
ConclusionAs far as could be ascertained, this is the first report of the in vivo induction, identification, and confirmation of a phenotype of the memory-like NK cells through a prophylactic effect via the use of an immunotherapeutic drug. Our findings provide novel insights into the in vivo induction of CD11bhighCD27low memory-like NK cells thus paving the way for the development of efficient immunotherapies.Graphical Abstract (Source: Experimental Hematology and Oncology)
Source: Experimental Hematology and Oncology - March 29, 2024 Category: Cancer & Oncology Source Type: research
VISTA drives macrophages towards a pro-tumoral phenotype that promotes cancer cell phagocytosis yet down-regulates T cell responses
ConclusionsCollectively, VISTA expression associates with and drives M2-like activation of macrophages with a high phagocytic capacity yet a decrease in antigen presentation capability to T cells. Therefore, VISTA is a negative immune checkpoint regulator in macrophage-mediated immune suppression. (Source: Experimental Hematology and Oncology)
Source: Experimental Hematology and Oncology - March 29, 2024 Category: Cancer & Oncology Source Type: research
Vaccination with a combination of STING agonist-loaded lipid nanoparticles and CpG-ODNs protects against lung metastasis via the induction of CD11bhighCD27low memory-like NK cells
ConclusionAs far as could be ascertained, this is the first report of the in vivo induction, identification, and confirmation of a phenotype of the memory-like NK cells through a prophylactic effect via the use of an immunotherapeutic drug. Our findings provide novel insights into the in vivo induction of CD11bhighCD27low memory-like NK cells thus paving the way for the development of efficient immunotherapies.Graphical Abstract (Source: Experimental Hematology and Oncology)
Source: Experimental Hematology and Oncology - March 29, 2024 Category: Cancer & Oncology Source Type: research
VISTA drives macrophages towards a pro-tumoral phenotype that promotes cancer cell phagocytosis yet down-regulates T cell responses
ConclusionsCollectively, VISTA expression associates with and drives M2-like activation of macrophages with a high phagocytic capacity yet a decrease in antigen presentation capability to T cells. Therefore, VISTA is a negative immune checkpoint regulator in macrophage-mediated immune suppression. (Source: Experimental Hematology and Oncology)
Source: Experimental Hematology and Oncology - March 29, 2024 Category: Cancer & Oncology Source Type: research
Cyclin dependent kinase 4/6 inhibitor palbociclib synergizes with BCL2 inhibitor venetoclax in experimental models of mantle cell lymphoma without RB1 deletion
ConclusionsOur data strongly support investigation of the chemotherapy-free palbociclib and venetoclax combination as an innovative treatment strategy for post-ibrutinib MCL patients withoutRB1 deletion. (Source: Experimental Hematology and Oncology)
Source: Experimental Hematology and Oncology - March 25, 2024 Category: Cancer & Oncology Source Type: research
Heat-killed Prevotella intermedia promotes the progression of oral squamous cell carcinoma by inhibiting the expression of tumor suppressors and affecting the tumor microenvironment
ConclusionsTaken together, our results suggest thatP.intermedia could inhibit the expression of tumor suppressors, alter the tumor microenvironment, and promote the progression of OSCC. (Source: Experimental Hematology and Oncology)
Source: Experimental Hematology and Oncology - March 21, 2024 Category: Cancer & Oncology Source Type: research
Ubiquitin ligase subunit FBXO9 inhibits V-ATPase assembly and impedes lung cancer metastasis
ConclusionThese findings collectively elucidate the critical role of FBXO9 in regulating V-ATPase assembly and provide a molecular basis for FBXO9 ’s function in inhibiting lung cancer metastasis. This highlights the potential therapeutic opportunities of FBXO9 supplementation. (Source: Experimental Hematology and Oncology)
Source: Experimental Hematology and Oncology - March 14, 2024 Category: Cancer & Oncology Source Type: research
